Mexico warns citizens after United States deportation of undocumented mother
Thomas Cook disappoints with first-quarter update as caution remains
U.S. oil output set to hit highest since 1970, says EIA
OPEC achieves 91% compliance with targeted cuts
Johnson & Johnson agrees to acquire biotech company Actelion for $30bn
27 January 2017, 12:44 | Felicia Christensen
After an off-and-on-again pursuit, Johnson & Johnson this morning landed Swiss biotech company Actelion in a $30 billion all-cash deal unanimously approved by both boards.
As part of the deal, worth $280 a share, Actelion will spin out its drug discovery unit, as well as its early-stage assets into a newly created Swiss biopharma known as the slightly uninspiring name of "R&D NewCo". J&J will initially hold 16 percent of the shares of R&D NewCo and will have rights to an additional 16 percent of its equity through a convertible note.
With the purchase, J&J - the world's biggest maker of healthcare products - is fulfilling its goal of adding a new drug category and dealing a blow to France's Sanofi, which also sought to acquire Actelion. The US behemoth expects the transaction to boost its long-term profit growth by as much as 2% over analysts' expectations. The transaction is expected to close by the end of the second quarter, with J&J commencing the tender offer by mid-February. J&J ended at US$112.80 in NY, capping a 11.5 per cent increase past year.
Actelion shares surged 21% to 273.90 Swiss francs as of 12.54pm, after having climbed 68% since early November. However, Johnson & Johnson withdrew from the discussions in mid-December, and Sanofi approached Actelion about a deal.
The companies plan to hold a call with investors at 8 a.m. This is the second time the French drugmaker will be left empty-handed, after losing out in August on Medivation, a biopharmaceutical that makes cancer treatments, to another USA giant, Pfizer.
Actelion pioneered the treatment of pulmonary arterial hypertension, or PAH, in 2001 with the introduction of Tracleer, and still dominates the $5 billion global market.
"The deal with J&J comes just days after Actelion reported that its marketed oral endothelin receptor antagonist, Opsumit (macitentan), failed to meet its primary endpoint in a Phase III study in patients with pulmonary arterial hypertension due to Eisenmenger Syndrome", according toGEN (Genetic Engineering and Biotechnology News).
The Clozels and a team of scientists who split from Roche Holding founded Actelion about 20 years ago. The CEO is a believer in Actelion's pipeline of experimental medicines, and he and his wife have resisted takeover bids through the years.
Lazard is acting as lead financial advisor to J&J and Citibank is also providing financial guidance. Bank of America is Actelion's lead adviser, with Credit Suisse Group also providing advice. Legal advisers to Actelion are Niederer Kraft & Frey; Wachtell, Lipton, Rosen & Katz; and Slaughter and May.
Japanese Ship Crew Caught Red-Handed Slaughtering Minke Whale
Sea Shepherd activists onboard its MY Steve Irwin boat alleged that they had encountered the Japanese ship in Australian waters. The dead animal was spotted on the Nisshin Maru whaling vessel in Australia's whale sanctuary in the waters of Antarctica.
Syria peace talks: 'Tense' discussions underway in Kazakhstan
Mr Assad has said he would give amnesty to insurgents who lay down their arms but they are unlikely to agree at this juncture. The local USA ambassador was present, while several Western envoys for Syria were also in Astana to observe developments.
Call Duffy on ACA repeal
Trump said additionally said insurance companies would pick up the costs for 'people that can afford it'. This is partly because each state has different health care regulations, so jurisdiction is important.
NFL PLAYOFFS: Elite QBs lead teams into championship games
Davis, who has emerged as the team's strong safety, told ESPN Thursday that he has not "felt like a rookie in a long time". Brown has put out an apology and according to coach Tomlin will be punished by the team. "I don't prepare for failure".
Zaza Pachulia Responds To Russell Westbrook's Threat
Durant jawed back and forth with his old teammates and it created a memorable game for the newest addition to Golden State. Later during a break in play, Durant even nonchalantly approached Westbrook and said something. "That's what they do".